Australia Just Approved a Weight Loss Drug That U.S. Hasn’t Even Tested

Australians are currently paying nearly $5,000 a year for Ozempic-like weight-management drugs in a pharmacy somewhere in Sydney or Melbourne. Every week, they take the injectable pens, carefully store them in the refrigerator, and inject themselves. For a significant portion of the population, needles are just not something they can comfortably handle over the long term, so while many people find success with this routine, others quietly fear or give it up. Orforglipron, an oral medication that could alter that computation, was approved by the FDA in early April 2026 and went on sale on April 6th for $149 per month under the brand name Foundayo in the United States. At some point this year, Australia’s Therapeutic Goods Administration is anticipated to follow. The medical professionals who are awaiting that decision are clearly excited.

The GLP-1 hormone is the same biological pathway used by Ozempic and Wegovy, but Eli Lilly’s orforglipron is a once-daily pill that doesn’t require an injection, cold-chain storage, or the stringent dosing window that Novo Nordisk’s oral Wegovy requires. Patients must take this pill first thing in the morning and wait 30 minutes before eating, drinking water, or taking any other medication. Novo introduced it in the US in January 2026, and in its first ten weeks, it has already reached about 400,000 American users. There are no such limitations with Foundayo. It can be taken with or without food at any time of day, which may seem insignificant until you take five minutes to consider the day-to-day struggles of someone who has small children at home, a complicated medication schedule, or shift work.

Orforglipron (Foundayo) & Australia’s Obesity Drug Landscape

tga.gov.au ↗

The co-founders of a number of Australian digital health businesses, including Mosh, My Weight Loss Clinic, and Eucalyptus, whose brands include Pilot and Juniper, told The Sydney Morning Herald that they were keeping a close eye on the TGA approval timeline and intended to stock the medication as soon as it arrived. Eucalyptus co-founder Tim Doyle was straightforward: “We will definitely be supplying both oral Wegovy and Foundayo when they reach our markets.” Needle aversion is a real obstacle to treatment uptake, according to Dr. Kieran Dang at Mosh, and an oral formulation could reach patients who have been delaying beginning a GLP-1 for years. For Australians living in rural and remote areas, where maintaining a steady supply of refrigerated medications is a real logistical challenge that frequently goes unaddressed in the primarily urban framework that governs Australian health policy, the lack of cold-chain requirements is also significant.

Orforglipron’s clinical outcomes are respectable but not outstanding. In a 36-week trial, patients lost an average of 15% of their body weight, while in a 72-week trial, the average was 12%. These figures fall short of what injectable Zepbound or Wegovy at higher doses typically produce, which is a significant constraint that physicians will take into account when making individual treatment decisions. For those who have followed the development of GLP-1 drugs, the most frequently reported side effects are gastrointestinal, such as nausea and vomiting. The FDA’s most serious label category, a boxed warning, was included with the approval. All of that is information that patients should be aware of before beginning treatment, but it does not disqualify a medication that targets a condition as serious to their health as obesity.

In a short period of time, Australia’s larger context surrounding these drugs has changed significantly. Ozempic was only TGA-approved for the treatment of type 2 diabetes as recently as 2024. Its extensive off-label use for weight loss was causing severe supply shortages, which irritated both the regulators attempting to control the medication and the diabetic patients who depended on it for medical purposes. By January 2026, Health Minister Mark Butler had promised to subsidize Wegovy through Australia’s Pharmaceutical Benefits Scheme for patients with a BMI of 35 or higher who were severely obese and had an established cardiovascular condition, such as those who had experienced a heart attack or stroke. In order to control what the minister himself referred to as a “very big bill for taxpayers,” the eligibility threshold is purposefully narrowed. However, it signifies a true change in the way Australia views obesity as a medical problem rather than a lifestyle one.

The rate of change is truly difficult to comprehend in real time when observing this from the viewpoint of someone attempting to predict where weight management medicine will go over the coming years. In clinical trials, retatrutide, the so-called “Triple G” medication under development at Eli Lilly, has demonstrated average weight losses of up to 29%; these figures surpass any currently approved worldwide. It has already produced results in type 2 diabetes studies that greatly outperform current treatments by adding glucagon to the tirzepatide formula, pushing the biological lever even harder. The precise time it will reach regulators, let alone patients in Australia or elsewhere, is still unknown. However, the direction is clear. The oral medication that Australia’s medical professionals are currently anxiously awaiting could be an intermediary step in a decade of pharmaceutical development that alters the fundamental clinical relationship between body weight and chronic illness in ways that are currently hard to fully predict.